Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

02-08-2017 | Children | Book chapter | Article

14. Islet Cell Transplantation

Authors: Antonio Bruni, Michael McCall, A. M. James Shapiro

Publisher: Springer Berlin Heidelberg

Login to get access

Abstract

For a subset of patients with complicated Type I Diabetes Mellitus (T1DM), islet transplantation has become a well-established treatment modality. Before 2000, fewer than 9% of islet transplant recipient maintained insulin independence for greater than one year. The improvements resulting from the Edmonton Protocol have led to high rates of one-year insulin independence, and together with an international collaboration, propagated the expansion of clinical islet transplantation centers worldwide. In spite of the continued success of clinical islet transplantation, a number of limitations with this therapy remain, including the requirement for lifelong immunosuppression with the associated side effects. While islet transplantation is currently generally reserved for adults with T1DM with severe hypoglycemia or glycemic lability, we herein consider the possibility of its application to the pediatric population, moving this therapy one day from a treatment for some to a potential cure for all.
Literature
1.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.PubMedCrossRef
2.
Polonsky KS. The past 200 years in diabetes. New Engl J Med. 2012;367(14):1332–40.PubMedCrossRef
3.
Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12(3):141–6.PubMedPubMedCentral
4.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329(14):977–86.CrossRef
5.
Keen H. The diabetes control and complications trial (DCCT). Health Trends. 1994;26(2):41–3.PubMed
6.
Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. New Engl J Med. 2003;348(23):2294–303.PubMedCrossRef
7.
Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61(6):827–37.PubMed
8.
Brogard JM, Vetter T, Blickle JF. Discovery of pancreatic diabetes in Strasbourg. Diabete Metabol. 1992;18(2):104–14.
9.
Agarwal A, Brayman KL. Update on islet cell transplantation for type 1 diabetes. Semin Intervent Radiol. 2012;29(2):90–8.PubMedPubMedCentralCrossRef
10.
Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16(1):35–9.PubMedCrossRef
11.
Misler S. The isolated pancreatic islet as a micro-organ and its transplantation to cure diabetes: celebrating the legacy of Paul Lacy. Islets. 2010;2(4):210–24.PubMedPubMedCentralCrossRef
12.
Reckard CR, Ziegler MM, Barker CF. Physiological and immunological consequences of transplanting isolated pancreatic islets. Surgery. 1973;74(1):91–9.PubMed
13.
Shapiro AM. A historical perspective on experimental and clinical islet transplantation. Informa Health Care. 2007;1.
14.
Lakey JR, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant. 1999;8(3):285–92.PubMedCrossRef
15.
Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes. 1989;38(Suppl 1):140–2.PubMedCrossRef
16.
Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New Engl J Med. 2000;343(4):230–8.PubMedCrossRef
17.
Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet transplant. Diabetes Obes Metab. 2006;8(1):1–7.PubMedCrossRef
18.
Scharp DW, Kemp CB, Knight MJ, Ballinger WF, Lacy PE. The use of ficoll in the preparation of viable islets of langerhans from the rat pancreas. Transplantation. 1973;16(6):686–9.PubMedCrossRef
19.
Najarian JS, Sutherland DE, Matas AJ, Steffes MW, Simmons RL, Goetz FC. Human islet transplantation: a preliminary report. Transpl Proc. 1977;9(1):233–6.
20.
Brendel M HB, Shulz A, Bretzel R. International islet transplant registry report. 1999.1–20.
21.
Benhamou PY, Watt PC, Mullen Y, Ingles S, Watanabe Y, Nomura Y, et al. Human islet isolation in 104 consecutive cases. Factors affecting isolation success. Transplantation. 1994;57(12):1804–10.PubMedCrossRef
22.
Goto M, Eich TM, Felldin M, Foss A, Kallen R, Salmela K, et al. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation. 2004;78(9):1367–75.PubMedCrossRef
23.
Ihm SH, Matsumoto I, Sawada T, Nakano M, Zhang HJ, Ansite JD, et al. Effect of donor age on function of isolated human islets. Diabetes. 2006;55(5):1361–8.PubMedCrossRef
24.
Lakey JR, Rajotte RV, Warnock GL, Kneteman NM. Human pancreas preservation prior to islet isolation. Cold ischemic tolerance. Transplantation. 1995;59(5):689–94.PubMedCrossRef
25.
Lakey JR, Warnock GL, Rajotte RV, Suarez-Alamazor ME, Ao Z, Shapiro AM, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation. 1996;61(7):1047–53.PubMedCrossRef
26.
Matsumoto I, Sawada T, Nakano M, Sakai T, Liu B, Ansite JD, et al. Improvement in islet yield from obese donors for human islet transplants. Transplantation. 2004;78(6):880–5.PubMedCrossRef
27.
Nano R, Clissi B, Melzi R, Calori G, Maffi P, Antonioli B, et al. Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia. 2005;48(5):906–12.PubMedCrossRef
28.
Zeng Y, Torre MA, Karrison T, Thistlethwaite JR. The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994;57(6):954–8.PubMedCrossRef
29.
Kin T, Murdoch TB, Shapiro AM, Lakey JR. Estimation of pancreas weight from donor variables. Cell Transplant. 2006;15(2):181–5.PubMedCrossRef
30.
Brandhorst H, Brandhorst D, Hering BJ, Federlin K, Bretzel RG. Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes. 1995;103(Suppl 2):23–6.PubMed
31.
Berney T, Johnson PR. Donor pancreata: evolving approaches to organ allocation for whole pancreas versus islet transplantation. Transplantation. 2010;90(3):238–43.PubMedCrossRef
32.
O’Gorman D, Kin T, Murdoch T, Richer B, McGhee-Wilson D, Ryan E, et al. The standardization of pancreatic donors for islet isolation. Transpl Proc. 2005;37(2):1309–10.CrossRef
33.
de Boer J, De Meester J, Smits JM, Groenewoud AF, Bok A, van der Velde O, et al. Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl Int. 1999;12(6):447–53.PubMedCrossRef
34.
Hering BJ, Matsumoto I, Sawada T, Nakano M, Sakai T, Kandaswamy R, et al. Impact of two-layer pancreas preservation on islet isolation and transplantation. Transplantation. 2002;74(12):1813–6.PubMedCrossRef
35.
Benhamou PY, Oberholzer J, Toso C, Kessler L, Penfornis A, Bayle F, et al. Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999–2000). Groupe de Recherche Rhin Rhjne Alpes Geneve pour la transplantation d’Ilots de Langerhans. Diabetologia. 2001;44(7):859–64.PubMedCrossRef
36.
Goss JA, Schock AP, Brunicardi FC, Goodpastor SE, Garber AJ, Soltes G, et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation. 2002;74(12):1761–6.PubMedCrossRef
37.
Wolters GH, Vos-Scheperkeuter GH, van Deijnen JH, van Schilfgaarde R. An analysis of the role of collagenase and protease in the enzymatic dissociation of the rat pancreas for islet isolation. Diabetologia. 1992;35(8):735–42.PubMedCrossRef
38.
Johnson PR, White SA, London NJ. Collagenase and human islet isolation. Cell Transplant. 1966;15(4):437–52.
39.
Wang X, Meloche M, Verchere CB, Ou D, Mui A, Warnock GL. Improving islet engraftment by gene therapy. J Transplant. 2011;2011:594851.PubMedPubMedCentral
40.
Mehigan DG, Bell WR, Zuidema GD, Eggleston JC, Cameron JL. Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation. Ann Surg. 1980;191(3):287–93.PubMedPubMedCentralCrossRef
41.
Lake SP, Bassett PD, Larkins A, Revell J, Walczak K, Chamberlain J, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes. 1989;38(Suppl 1):143–5.PubMedCrossRef
42.
Ichii HPA, Khan A, Fraker C, Ricordi C. Culture and transportation of human islets between centers. Islet transplantation and beta cell replacement therapy. New York: Informa healthcare; 2007. p. 251.CrossRef
43.
Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293(7):830–5.PubMedCrossRef
44.
Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbaro B, Kuechle JB, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant. 2008;8(6):1250–61.PubMedCrossRef
45.
Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5(8):2037–46.PubMedCrossRef
46.
Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, Ponte GM, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86(1):36–45.PubMedPubMedCentralCrossRef
47.
Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83(1):24–8.PubMedCrossRef
48.
Faradji RN, Tharavanij T, Messinger S, Froud T, Pileggi A, Monroy K, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation. 2008;86(12):1658–65.PubMedPubMedCentralCrossRef
49.
Rajab A. Islet transplantation: alternative sites. Curr Diab Rep. 2010;10(5):332–7.PubMedCrossRef
50.
Froud T, Yrizarry JM, Alejandro R, Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. 2004;13(1):55–9.PubMedCrossRef
51.
Barshes NR, Lee TC, Goodpastor SE, Balkrishnan R, Schock AP, Mote A, et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg. 2005;200(3):353–61.PubMedCrossRef
52.
Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes. 2002;51(1):66–72.PubMedCrossRef
53.
Owen RJ, Ryan EA, O’Kelly K, Lakey JR, McCarthy MC, Paty BW, et al. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology. 2003;229(1):165–70.PubMedCrossRef
54.
Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–9.PubMedCrossRef
55.
Gala-Lopez B, Pepper AR, Shapiro AM. Biologic agents in islet transplantation. Curr Diab Rep. 2013;13(5):713–22.PubMedCrossRef
56.
Bloom SR, Polak JM. Somatostatin. Br Med J. 1987;295(6593):288–90.CrossRef
57.
Korsgren O, Lundgren T, Felldin M, Foss A, Isaksson B, Permert J, et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia. 2008;51(2):227–32.PubMedCrossRef
58.
Shapiro AM. A historical perspective on experimental and clinical islet transplantation. In: Shapiro AM, Shaw JA, editors. Islet transplantation and beta cell replacement therapy. New York, London: Informa Healthcare; 2007.CrossRef
59.
Gabardi S, Martin ST, Roberts KL, Grafals M. Induction immunosuppressive therapies in renal transplantation. Am J Health-System Pharm: AJHP: Official J Am Soc Health-System Pharmacists. 2011;68(3):211–8.CrossRef
60.
Hering BJ. Repurification: rescue rather than routine remedy. Am J Transplant. 2005;5(1):1–2.PubMedCrossRef
61.
Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation. 2010;89(4):465–71.PubMedCrossRef
62.
Matsumoto S, Takita M, Chaussabel D, Noguchi H, Shimoda M, Sugimoto K, et al. Improving efficacy of clinical islet transplantation with iodixanol based islet purification, Thymoglobulin induction and blockage of IL-1-beta and TNF-alpha. Cell Transplant. 2011;20(10):1641–7.
63.
Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant. 2004;4(3):295–8.PubMedCrossRef
64.
Xenos ES, Farney AC, Widmer MB, Casanova D, Stevens RB, Blazar BR, et al. Effect of tumor necrosis factor alpha and of the soluble tumor necrosis factor receptor on insulin secretion of isolated islets of Langerhans. Transpl Proc. 1992;24(6):2863–4.
65.
Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant. 2005;5(9):2318–23.PubMedCrossRef
66.
Kaplan B, Schold J, Srinivas T, Womer K, Foley DP, Patton P, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant. 2004;4(10):1709–12.PubMedCrossRef
67.
The CITR Coordinating Center and Investigators. The collaborative islet transplant registry (CITR) 2011 seventh annual report. https://​web.​emmes.​com/​study/​isl/​reports/​01062012_​7thAnnualReport.​pdf. Accessed 27 Jan 2017.
68.
Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35(7):1436–45.PubMedPubMedCentralCrossRef
69.
Senior PA, Kin T, Shapiro AMJ, Koh A. Islet transplantation at the University of Alberta: status update and review of progress over the last decade. Can J Diabetes. 2012;36:32–7.CrossRef
70.
Pepper AR, Gala-Lopez B, Ziff O, Shapiro AJ. Current status of clinical islet transplantation. World J Transplant. 2013;3(4):48–53.PubMedPubMedCentral
71.
Senior PAKT, Shapiro AMJ, Koh A. Islet transplantation at the University of Alberta: Status update and review of progress over the last decade. Can J Diabetes. 2012;36:32–7.CrossRef
72.
Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310(12):1240–7.PubMedCrossRef
73.
Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Transplant. 2011;16(6):627–31.PubMedPubMedCentralCrossRef
74.
Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011;91(3):373–8.PubMedCrossRef
75.
Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955–62.PubMedCrossRef
76.
Patrick AW, Campbell IW. Fatal hypoglycaemia in insulin-treated diabetes mellitus: clinical features and neuropathological changes. Diabet Med. 1990;7(4):349–54.PubMedCrossRef
77.
Gonder-Frederick LA, Clarke WL, Cox DJ. The Emotional, Social, and Behavioral Implications of Insulin-Induced Hypoglycemia. Semin Clin Neuropsychiatry. 1997;2(1):57–65.PubMed
78.
Hathout E, Lakey J, Shapiro J. Islet transplant: an option for childhood diabetes? Arch Dis Child. 2003;88(7):591–4.PubMedPubMedCentralCrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Image Credits